MFC Co., Ltd.
KKRX:4329802,325.00
KRW
+80.00
(+3.56%)
ISIN
KR7432980001
Return %
Stock
S&P 500
1Y
-41.51
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 65
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hwaseong-si South Korea
- Website
- mfcglobal.co.kr
- Similar Companies
- Business
- MFC Co., Ltd. is a South Korea-based pharmaceutical manufacturing and development company specializing in high-purity active pharmaceutical ingredients (APIs), key pharmaceutical intermediates, and contract development and manufacturing organization (CDMO) services. Founded in 2008 and headquartered in Hwaseong, Gyeonggi Province, South Korea, the company leverages proprietary synthesis and high-purity crystallization technologies to produce and commercialize advanced chemical materials for domestic and international pharmaceutical corporations. The company operates through three principal business segments: Active Pharmaceutical Ingredients, Key Intermediates and Starting Materials, and CDMO/CMO Services. Its commercial product and service portfolio comprises: Active Pharmaceutical Ingredients (APIs), including pitavastatin calcium and rosuvastatin calcium for hyperlipidemia and cardiovascular treatments; donepezil hydrochloride for Alzheimer's disease therapeutics; clopidogrel bisulfate for antithrombotic therapies; ilaprazole for gastrointestinal disorders; gemigliptin for type 2 diabetes management; and varenicline for smoking cessation; Key Intermediates and Raw Materials, featuring crystallized tert-butyl (6-amino-2,2-dimethyl-1,3-dioxan-4-yl)acetate (TBFA) and triphenylphosphonium bromide (TPPBr) statin starting materials, alongside high-purity custom intermediates for small-molecule chemical synthesis; CDMO and CMO Services, encompassing chemical route exploration, polymorph screening, crystallization engineering, scale-up synthesis, cGMP-compliant batch production, and regulatory filing support; and Next-Generation Therapeutic Technologies, consisting of antibody-drug conjugate (ADC) linkers, payload-linker intermediates, and artificial intelligence-driven pharmaceutical formulation research. The company maintains BGMP-certified manufacturing and R&D facilities at the Cheongwon Industrial Complex in Hwaseong, South Korea, and holds Foreign Manufacturer Accreditation from Japan's Ministry of Health, Labour and Welfare (MHLW), distributing products across South Korea, Japan, and broader global markets. In recent corporate developments, MFC Co., Ltd. completed a merger with Hana Financial 21st Special Purpose Acquisition Company (Hana Financial 21 SPAC) and officially listed its shares on the KOSDAQ market (KRX: 432980) in December 2024. To meet growing domestic and international demand, the company initiated the expansion of its manufacturing footprint through the construction of a second production plant at its Hwaseong headquarters, designed to more than double its aggregate API and intermediate manufacturing capacity. In commercial partnerships, MFC Co., Ltd. established strategic supply and co-development agreements with major pharmaceutical partners, including Huons and JW Pharmaceutical, for the development and long-term supply of key raw materials for incrementally modified drugs and combination therapies. Furthermore, the company has broadened its core capabilities into high-value biopharmaceutical segments, establishing an AI formulation research center and initiating research programs for ADC linkers and novel therapeutic substances.